More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval

Closing Down Jardiance’s Lead

 
• By Andrew McConaghie

AstraZeneca’s SGLT2 inhibitor produced 50% growth in Q1, and its new chronic kidney disease approval will give it an edge over Lilly and Boehringer’s Jardiance.

AZ building
Farxiga has emerged as the company's star performer in its cardiovascular, renal and metabolism franchise. • Source: Alamy

More from Business

More from Scrip